Nath Bio-Genes (India) Ltd. (NATHBIOGEN) AI Stock Analysis

Nath Bio-Genes (India) Ltd.

(NSE:NATHBIOGEN)

Select Model

Rating:60Neutral

Price Target:INR 138.00▲(4.94% Upside)

Action:downgraded

Date:08/11/26

Cash flow volatility and bearish technical indicators weigh on the score, offset by a solid balance sheet and attractive valuation; moderate financial performance reflects recovery potential amid sector cycles.

Positive Factors

Revenue GrowthThe reported revenue-growth rate indicates expanding sales activity and improving market reach for the seed portfolio. If this growth is sustained through the agricultural cycle, it can support greater operating scale, strengthen channel presence, and provide a foundation for continued investment in product development and commercialization.

Negative Factors

Weak Cash ConversionNegative operating and free cash flow despite positive reported earnings raises concern about how reliably accounting profits convert into usable funds. Continued weak conversion could constrain investment, increase reliance on working-capital financing, and reduce management’s flexibility during the company’s seasonal operating cycle.

Nath Bio-Genes (India) Ltd. (NATHBIOGEN) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 2.49B
Dividend Yield: 1.52%
Average Volume (3M): 1,084
Price to Earnings (P/E): 7.1
Beta (1Y): 1.12
Revenue Growth: 21.02%
EPS Growth: -3.13%
Country: India
Employees: 452
Sector: General
Sector Strength: 55
Industry: Agricultural Inputs

Nath Bio-Genes (India) Ltd. Business Overview & Revenue Model

Company Description

Nath Bio-Genes (India) Limited is dedicated to the development, preparation, and worldwide distribution of both hybrid and genetically modified (GM) seeds, catering to demand within India and internationally. Its business operations are organized int...

How the Company Makes Money

Nath Bio-Genes primarily makes money by selling seeds to the domestic agricultural market through its marketing and distribution network. Its main revenue stream is the sale of proprietary and third-party seeds (typically including hybrid seeds, wher...

Nath Bio-Genes (India) Ltd. Financial Statement Overview

Summary

Blended assessment from income statement (65: volatile revenue but improving margins), balance sheet (80: steady asset growth and low leverage), and cash flow (45: inconsistent operations with negative flows in some years) indicates moderate financial health with strengths in equity stability but risks from cash volatility.

Income Statement

65Positive

Balance Sheet

80Positive

Cash Flow

45Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	4.90B	4.45B	3.65B	2.48B	3.01B	2.78B
Gross Profit	2.12B	2.04B	2.29B	1.03B	1.67B	1.54B
EBITDA	613.59M	662.56M	497.98M	536.39M	488.91M	-497.06M
Net Income	386.75M	416.30M	386.00M	396.19M	350.11M	-673.38M
Balance Sheet
Total Assets	0	10.97B	10.26B	8.80B	7.93B	7.42B
Cash, Cash Equivalents and Short-Term Investments	759.95M	759.95M	888.99M	774.10M	379.90M	41.68M
Total Debt	0	1.39B	1.23B	1.10B	1.05B	929.59M
Total Liabilities	-6.80B	4.17B	3.82B	2.70B	2.20B	2.00B
Stockholders Equity	6.80B	6.80B	6.44B	6.10B	5.73B	5.42B
Cash Flow
Free Cash Flow	-1.10B	-250.40M	96.61M	478.18M	358.18M	-39.70M
Operating Cash Flow	-1.09B	-220.35M	175.81M	745.94M	383.67M	170.46M
Investing Cash Flow	-11.48M	-30.69M	-39.62M	-274.01M	-28.84M	-198.66M
Financing Cash Flow	216.74M	122.00M	-21.30M	-77.78M	-16.68M	-222.27M

Nath Bio-Genes (India) Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price131.50

Price Trends

50DMA143.67Negative

100DMA152.29Negative

200DMA152.74Negative

Market Momentum

MACD-3.67Negative

RSI38.92Neutral

STOCH34.20Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATHBIOGEN, the sentiment is Negative. The current price of 131.50 is below the 20-day moving average (MA) of 134.94, below the 50-day MA of 143.67, and below the 200-day MA of 152.74, indicating a bearish trend. The MACD of -3.67 indicates Negative momentum. The RSI at 38.92 is Neutral, neither overbought nor oversold. The STOCH value of 34.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NATHBIOGEN.

Nath Bio-Genes (India) Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:NATHBIOGEN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:SHARDACROP	76Outperform	INR 59.96B	9.58	―	2.26%	18.52%	49.11%
IN:DHANUKA	73Outperform	INR 43.75B	16.48	―	0.20%	-5.63%	-11.38%
IN:IPL	66Neutral	INR 12.97B	12.05	―	0.67%	17.05%	9.10%
IN:RALLIS	63Neutral	INR 35.75B	18.14	―	1.63%	6.82%	11.93%
IN:NATHBIOGEN	60Neutral	INR 2.50B	7.11	―	1.52%	21.02%	-3.13%
IN:INSECTICID	58Neutral	INR 15.10B	11.82	―	0.39%	1.26%	-16.43%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:NATHBIOGEN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:NATHBIOGEN	Nath Bio-Genes (India) Ltd.	131.50	-37.81	-22.33%
IN:DHANUKA	Dhanuka Agritech Limited	981.50	-322.04	-24.70%
IN:INSECTICID	Insecticides (India) Limited	519.10	-200.11	-27.82%
IN:IPL	India Pesticides Ltd.	112.60	-77.23	-40.68%
IN:RALLIS	Rallis India Limited	183.85	-75.13	-29.01%
IN:SHARDACROP	Sharda Cropchem Ltd.	664.60	-135.86	-16.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 11, 2026

Nath Bio-Genes (India) Ltd. AI Stock Analysis